MedTrace Logo

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

NCT01122199 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-05-10

No results posted yet for this study

Summary

The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.

Conditions

  • Neoplasm Metastases

Interventions

DRUG

RAD001 + AMG479

Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Shadia Jalal

    lead OTHER

Principal Investigators

  • Shadia I Jalal, MD · Indiana University Melvin and Bren Simon Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-14
Primary Completion
2015-01-19
Completion
2015-01-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122199 on ClinicalTrials.gov